Medpage Today on MSN22h
SGLT1/2 Inhibitor Cut Stroke, Heart Attack Risk in Diabetic Kidney Disease
The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...
GlobalData on MSN5d
Boehringer seeks approval of lung disease drug after second Phase III success
Boehringer Ingelheim’s lung disease drug nerandomilast has been successful in a Phase III study paving the way for the ...
Pharmabiz15h
Boehringer Ingelheim introduces Semintra 4 mg/ml oral solution in Europe to treat chronic kidney disease and hypertension in cats
Ingelheim, Germany Saturday, February 15, 2025, 12:00 Hrs [IST] ...
BioSpace5d
Boehringer Ingelheim’s Lung Fibrosis Drug Scores Second Late-Stage Win
Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...
Managed Healthcare Executive8h
More Results for Nerandomilast Reported by BI, This Time for Progressive Pulmonary Fibrosis
Several weeks after reporting positive results for nerandomilast for idiopathic pulmonary fibrosis, Boehringer Ingelheim reported positive results from a similar phase 3 trial assessing its PDE4B ...
ExpressionEdits Collaborates with Boehringer Ingelheim to Develop Enhanced Gene Therapies
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.BoQAct6R.js ...
Healio2d
Positive topline data reported in phase 3 trial of nerandomilast in progressive PF
Adults with progressive pulmonary fibrosis met the primary endpoint of absolute change in FVC with 52-week oral nerandomilast ...
The American Journal of Managed Care1d
Nerandomilast Improves Lung Function in Progressive Pulmonary Fibrosis: FIBRONEER-ILD
Patients with progressive pulmonary fibrosis who received nerandomilast showed improved forced vital capacity from baseline ...
FierceBiotech5d
Boehringer widens fibrosis drug's approval path after boosting lung function in 2nd phase 3 trial
Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in ...
pharmaphorum4d
Boehringer drug scores in another pulmonary fibrosis trial
The two positive studies mean that Boehringer can now seek approval for nerandomilast with a broad label claim in pulmonary ...
Pharmabiz3d
Boehringer Ingelheim’s FIBRONEER-ILD phase III study of nerandomilast to treat progressive pulmonary fibrosis meets primary endpoint
Boehringer Ingelheim’s FIBRONEER-ILD phase III study of nerandomilast to treat progressive pulmonary fibrosis meets primary endpoint: Ingelheim, Germany Wednesday, February 12, ...